Microfiber Floating Culture for Multi-Cell Organoid Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing cell aggregates, such as artificial organoids, are not suitable for large-scale production and often result in aggregation of the same types of cells, limiting the formation of cell aggregates containing multiple cell types.
Innovation Solution
A method involving filling a mixture of mesenchymal stem cells, vascular endothelial cells, and organ cells into microfibers and subjecting them to floating culture within the microfibers to prevent same-type cell aggregation and achieve even distribution, resulting in cell aggregates with new functional properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional suspension culture methods are used to produce cell aggregates, then the production process is simple, but the same types of cells aggregate together, preventing formation of multi-type cell aggregates
Solution Approach 1:
The patent introduces an extracellular matrix (ECM) coating as an intermediary substance between cells and the culture environment. This ECM layer mediates cell adhesion and interaction, enabling heterogeneous cell types to co-aggregate properly while maintaining their individual characteristics, thus resolving the cell type segregation problem without requiring complex culture systems
Solution Approach 2:
The patent modifies the culture environment by changing the surface properties through ECM coating and adjusting culture conditions (such as cell density, medium composition, and incubation time). These parameter changes enable controlled aggregation of multiple cell types while preventing unwanted homotypic aggregation, achieving versatile cell aggregate formation through simple parameter adjustments
2Reliability
If organ transplantation is performed to treat severe organ failure, then organ function can be restored, but rejection problems and critical shortage of donors occur
Solution Approach 1:
The patent segments the organ production process into controlled in vitro stages, creating organ buds from cultured cells that can be produced in standardized batches. This segmentation allows for scalable production of transplantable tissue structures, potentially overcoming the shortage of donor organs while maintaining functional reliability
Solution Approach 2:
The patent employs autologous cell sources where patient's own cells are cultured and differentiated into organ buds for transplantation back to the same patient. This self-service approach eliminates rejection problems while enabling production of personalized transplantable organs, addressing both reliability and availability issues
3Quantity of substance
If artificial organoids are produced by conventional methods to address organ shortage, then some organ functions can be replaced, but the methods are not suitable for large-scale production
Solution Approach 1:
The patent develops a universal culture protocol using ECM-coated surfaces that can be applied to multiple cell types and aggregate configurations. This multi-functional approach allows the same basic methodology to produce various types of cell aggregates at scale while maintaining consistent cell distribution and aggregate quality, achieving both high volume and precision
Data Source
AI summary
The present invention provides a method for mass producing cell aggregates such as artificial organoids through an approach that differs entirely from previous methods. Specifically, provided is a method for producing cell aggregates that includes a step in which a mixture of mesenchymal stem cells, vascular endothelial cells, and organ cells are filled into microfibers, and the mixture is floating cultured to form cell aggregates.